ADVM
Price:
$4.74
Market Cap:
$98.60M
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorpor...[Read more]
Industry
Biotechnology
IPO Date
2014-07-31
Stock Exchange
NASDAQ
Ticker
ADVM
According to Adverum Biotechnologies, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 79.02M. This represents a change of -29.59% compared to the average of 112.22M of the last 4 quarters.
The mean historical Enterprise Value of Adverum Biotechnologies, Inc. over the last ten years is 2.04B. The current 79.02M Enterprise Value has changed 287.92% with respect to the historical average. Over the past ten years (40 quarters), ADVM's Enterprise Value was at its highest in in the June 2020 quarter at 16.76B. The Enterprise Value was at its lowest in in the December 2023 quarter at 76.25M.
Average
2.04B
Median
860.12M
Minimum
75.96M
Maximum
12.13B
Discovering the peaks and valleys of Adverum Biotechnologies, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 108.58%
Maximum Annual Enterprise Value = 12.13B
Minimum Annual Increase = -82.14%
Minimum Annual Enterprise Value = 75.96M
Year | Enterprise Value | Change |
---|---|---|
2023 | 75.96M | -20.83% |
2022 | 95.94M | -60.25% |
2021 | 241.35M | -72.92% |
2020 | 891.27M | 26.46% |
2019 | 704.81M | -60.37% |
2018 | 1.78B | 21.99% |
2017 | 1.46B | 75.88% |
2016 | 828.96M | -61.74% |
2015 | 2.17B | -82.14% |
2014 | 12.13B | 108.58% |
The current Enterprise Value of Adverum Biotechnologies, Inc. (ADVM) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
137.75M
5-year avg
401.86M
10-year avg
2.04B
Adverum Biotechnologies, Inc.’s Enterprise Value is less than uniQure N.V. (661.66M), less than Rocket Pharmaceuticals, Inc. (1.20B), less than Rhythm Pharmaceuticals, Inc. (3.39B), less than Solid Biosciences Inc. (127.34M), less than MeiraGTx Holdings plc (446.07M), greater than Aerovate Therapeutics, Inc. (44.50M), greater than Adagene Inc. (11.00M), less than Acrivon Therapeutics, Inc. Common Stock (154.58M), less than Rezolute, Inc. (247.14M), greater than AN2 Therapeutics, Inc. (7.13M), greater than Passage Bio, Inc. (33.76M), less than Absci Corporation (319.51M), greater than Kezar Life Sciences, Inc. (29.92M), greater than Oncternal Therapeutics, Inc. (-11329454.00), less than Kodiak Sciences Inc. (394.97M), greater than Galmed Pharmaceuticals Ltd. (-4686750.00), greater than Affimed N.V. (23.63M), less than Mereo BioPharma Group plc (510.15M), greater than Homology Medicines, Inc. (-103303255.00), less than Stoke Therapeutics, Inc. (451.87M), greater than Atreca, Inc. (-8620212.00), less than TCR2 Therapeutics Inc. (79.12M),
Company | Enterprise Value | Market cap |
---|---|---|
661.66M | $845.69M | |
1.20B | $1.24B | |
3.39B | $3.43B | |
127.34M | $167.01M | |
446.07M | $482.21M | |
44.50M | $75.07M | |
11.00M | $85.89M | |
154.58M | $193.98M | |
247.14M | $255.53M | |
7.13M | $40.64M | |
33.76M | $40.24M | |
319.51M | $345.72M | |
29.92M | $47.86M | |
-11329454.00 | $1.56M | |
394.97M | $519.40M | |
-4686750.00 | $5.04M | |
23.63M | $18.88M | |
510.15M | $589.54M | |
-103303255.00 | $3.02M | |
451.87M | $599.59M | |
-8620212.00 | $3.57M | |
79.12M | $58.11M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Adverum Biotechnologies, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Adverum Biotechnologies, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Adverum Biotechnologies, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Adverum Biotechnologies, Inc. (ADVM)?
What is the 3-year average Enterprise Value for Adverum Biotechnologies, Inc. (ADVM)?
What is the 5-year average Enterprise Value for Adverum Biotechnologies, Inc. (ADVM)?
How does the current Enterprise Value for Adverum Biotechnologies, Inc. (ADVM) compare to its historical average?